ENGAGE-501; Phase II study investigating the role of epigenetic therapy with entinostat (SNDX-275) hi relapsed and refractory Hodgkin's lymphoma (HL)

被引：2
|
作者：
Younes, A.
Rosen, P. J.
Hernandez-Ilizaliturri, F. J.
Bociek, G.
Kasamon, Y. L.
Copeland, A.
Lee, G. T.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Tower Canc Res Fdn, Beverly Hills, CA USA
[3] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[4] Univ Nebraska Med Ctr, Omaha, NE USA
[5] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[6] Syndax Pharmaceut Inc, Waltham, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.tps298
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS298
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ENGAGE-501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma
    Batlevi, Connie Lee
    Kasamon, Yvette
    Bociek, R. Gregory
    Lee, Peter
    Gore, Lia
    Copeland, Amanda
    Sorensen, Rachel
    Ordentlich, Peter
    Cruickshank, Scott
    Kunkel, Lori
    Buglio, Daniela
    Hernandez-Ilizaliturri, Francisco
    Younes, Anas
    HAEMATOLOGICA, 2016, 101 (08) : 968 - 975
  • [2] ENGAGE-501: Phase 2 Study Investigating the Role of Epigenetic Therapy with Entinostat (SNDX-275) In Relapsed and Refractory Hodgkin's Lymphoma (HL), Interim Results
    Younes, Anas
    Hernandez, Francisco
    Bociek, R. Gregory
    Kasamon, Yvette L.
    Lee, Peter
    Gore, Lia
    Buglio, Daniela
    Copeland, Amanda
    BLOOD, 2010, 116 (21) : 1614 - 1615
  • [3] The HDAC Inhibitor Entinostat (SNDX-275) Induces Clinical Responses in Patients with Relapsed and Refractory Hodgkin's Lymphoma: Results of ENGAGE-501 Multicenter Phase 2 Study
    Younes, Anas
    Hernandez, Francisco
    Bociek, R. Gregory
    Kasamon, Yvette L.
    Lee, Peter
    Gore, Lia
    Copeland, Amanda R.
    BLOOD, 2011, 118 (21) : 1168 - 1168
  • [4] Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL).
    Sermer, David J.
    Vardhana, Santosha Adipudi
    Ames, Ashley
    Biggar, Erin
    Moskowitz, Alison J.
    Batlevi, Connie Lee
    Caron, Philip
    Hamilton, Audrey M.
    Moskowitz, Craig H.
    Matasar, Matthew J.
    Zelenetz, Andrew David
    Horwitz, Steven M.
    Von Keudell, Gottfried
    Yahalom, Joachim
    Rademaker, Jurgen
    Dogan, Ahmet
    Seshan, Venkatraman E.
    Younes, Anas
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma
    Hosein, Peter J.
    Craig, Michael D.
    Tallman, Martin S.
    Boccia, Ralph V.
    Hamilton, Brian L.
    Lewis, Jonathan J.
    Lossos, Izidore S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (01) : 111 - 114
  • [6] Phase II trial of gemcitabine in patients (pts) with relapsed or chemotherapy-refractory Hodgkin's lymphoma (HL).
    Venkatesh, H
    Di Bella, NJ
    Cuasay, LC
    Vellek, M
    Mirabel, M
    Asmar, L
    BLOOD, 2002, 100 (11) : 300B - 300B
  • [7] Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL)
    Sermer, David J.
    Vardhana, Santosha
    Biggar, Erin
    Moskowitz, Alison J.
    Joffe, Erel
    Khan, Niloufer
    Straus, David J.
    Kumar, Anita
    Zelenetz, Andrew D.
    Horwitz, Steven M.
    Noy, Ariela
    Batlevi, Connie Lee
    Hamilton, Audrey
    Owens, Colette
    Matasar, Matthew J.
    Palomba, M. Lia
    Lee, Christina Y.
    Falchi, Lorenzo
    Johnson, William T.
    Schoder, Heiko
    Dogan, Ahmet
    Bunyaviroch, Tira
    Seshan, Venkatraman
    Salles, Gilles
    Younes, Anas
    Von Keudell, Gottfried
    BLOOD, 2021, 138
  • [8] Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
    Younes, Anas
    Gopal, Ajay K.
    Smith, Scott E.
    Ansell, Stephen M.
    Rosenblatt, Joseph D.
    Savage, Kerry J.
    Ramchandren, Radhakrishnan
    Bartlett, Nancy L.
    Cheson, Bruce D.
    de Vos, Sven
    Forero-Torres, Andres
    Moskowitz, Craig H.
    Connors, Joseph M.
    Engert, Andreas
    Larsen, Emily K.
    Kennedy, Dana A.
    Sievers, Eric L.
    Chen, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (18) : 2183 - 2189
  • [9] Phase I/II Study of Dasatinib In Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
    William, Basem M.
    Hohenstein, Maribeth
    Loberiza, Fausto R., Jr.
    Caponetti, Gabriel C.
    Bociek, R. Gregory
    Bierman, Philip
    Armitage, James O.
    Chan, Wing-Chung
    Vose, Julie M.
    BLOOD, 2010, 116 (21) : 131 - 131
  • [10] Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma
    Ribrag, Vincent
    Caballero, Dolores
    Ferme, Christophe
    Zucca, Emanuele
    Arranz, Reyes
    Briones, Javier
    Gisselbrecht, Christian
    Salles, Gilles
    Gianni, Alessandro M.
    Gomez, Henry
    Kahatt, Carmen
    Corrado, Claudia
    Szyldergemajn, Sergio
    Extremera, Sonia
    de Miguel, Bernardo
    Cullell-Young, Martin
    Cavalli, Franco
    HAEMATOLOGICA, 2013, 98 (03) : 357 - 363
12345